1 injection of potent juice every 39-52 weeks for RA patients who are resistant to or intolerant of anti-TNF or other biologic agents.
At 12, 39 and 52 weeks:
- the MPC 2M/kg group significantly outperformed placebo at every time point for ACR-N Area Under the Curve (AUC) (p=0.05 at 12 weeks, p=0.004 at 39 weeks, and p=0.008 at 52 weeks), indicating a robust, durable and consistent clinical effect of this MPC dose.
Mesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell, page-3
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.71 |
Change
0.010(0.59%) |
Mkt cap ! $2.163B | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.71 | $1.64 | $2.634M | 1.575M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 35244 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.71 | 28509 | 22 |
View Market Depth
| Last trade - 14.31pm 16/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |